Obsidian fills CEO, CDO roles with Iovance vets
Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more
Cell and gene therapy company Obsidian Therapeutics Inc. hired Madan Jagasia as CEO and Parameswaran Hari as chief development officer. Both were most recently at Iovance Biotherapeutics Inc. (NASDAQ:IOVA), where Jagasia was EVP, medical affairs, and Hari was SVP, clinical science.
Jami Rubin became a venture partner at Arch Venture Partners. Rubin was CFO at EQRx Inc. (NASDAQ:EQRX) and is a 20-plus-year veteran of Goldman Sachs, where she covered the biopharma industry as an equity analyst...